The effect of 30 day krill oil supplementation on cardiovascular risk factors
Investigation of krill oil and cardio-metabolic risk factors in healthy women
Victoria University
30 participants
May 12, 2015
Interventional
Conditions
Summary
The health benefits of long-chain n-3 polyunsaturated fatty acids are associated with the incorporation of EPA and DHA into the cell membrane which then alters the membrane structure and cell functions. Consequently they reduce plasma triglyceride level, inhibit inflammatory response, suppress thrombosis process. Krill oil and fish oil are rich sources of EPA and DHA. The bio-availability of these fatty acids from the two oils maybe different due to chemical structure of the oils. This study will evaluate the incorporation of EPA and DHA into the red blood cell membrane. In addition the effects on cardio-metabolic risk factors will also be investigated.
Eligibility
Inclusion Criteria1
- Females have not experienced menopause, body mass index (BMI) between 20 and 30 (kg/m2).
Exclusion Criteria1
- Cigarette smoker; all types of heart, liver or kidney disease, diabetes; pregnancy; lactating; medications of cholesterol lowering, anti-hypertension, anti-inflammation, anti-coagulation or anti-depression; omega-3 or antioxidant supplements in the past four weeks prior to the study.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Ingestion of krill oil capsules daily containing 1.7g of total EPA + DPA + DHA daily for 30 days followed by 30 days washout period. The break-down concentration for individual fatty acids are: 1086mg EPA, 611mg DHA and 32mg of DPA. Adherence to intervention protocols will be monitored at day 0, 5, 10, 15 and 30 through clinical visits - capsule calendar will be collected at each visit.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12615000472572